Report
EUR 14.23 For Business Accounts Only

ADCOCK-INGRAM HDG.LTD. is slightly downgraded to Slightly Positive due to an increasingly adverse environment

The independent financial analyst theScreener just slightly lowered the general evaluation of ADCOCK-INGRAM HDG.LTD. (ZA), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis date April 17, 2020, the closing price was ZAR 45.00 and its potential was estimated at ZAR 50.02.
Underlying
Adcock Ingram Holdings

Adcock Ingram Holdings is principally engaged as a manufacturer, marketer and distributor of healthcare products. Co.'s product portfolio includes branded and generic prescription medicines and over the counter/fast moving consumer goods brands, intravenous products, blood collection products and renal dialysis systems. Co. operates within three segments: over the counter, which comprises pharmaceutical products available without prescription as well as personal care products; prescription, which comprises products available on prescription only; and hospital products.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch